0
AnaptysBio, Inc. Banner Image

AnaptysBio, Inc. has reached its limit for free report views

Work for AnaptysBio, Inc.? Upgrade Your Profile and unlock all your annual reports.

AnaptysBio, Inc.

  • Ticker ANAB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
AnaptysBio, Inc. Logo Image
  • 51-200 Employees
  • Based in San Diego, California
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody etokimab, previously referred to as ANB020, for the treatment of chronic rhinosinusitis withMore nasal polyps, or CRSwNP, and eosinophilic asthma; its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi and ichthyosis; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (dostarlimab (GSK4057190A)), an anti-TIM-3 antagonist antibody (GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.
AnaptysBio, Inc.

Most Recent Annual Report

AnaptysBio, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. AnaptysBio, Inc. has reached its limit for free report views.

Older/Archived Annual Reports